GlassScriptPhysician profile
Kala Seetharman
NPI 1710969050
$7,879.03
in general payments reported to CMS, 2019-2025
36 companies · $1,916 in 2025
The $1,916 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,429 · 2020: $308 · 2021: $84.89 · 2022: $169 · 2023: $558 · 2024: $1,415 · 2025: $1,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,788 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.47 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $2,670.98 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $965.07 | 2019-2025 | Enhertu, Imfinzi, Epanova |
| Eisai INC. | $523.88 | 2019-2025 | |
| Exelixis INC. | $395.31 | 2019-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $374.97 | 2019-2024 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $318.96 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Biotech, INC. | $300.47 | 2019-2025 | Erleada, Rybrevant, Akeega |
| Stemline Therapeutics INC. | $237.30 | 2023-2024 | Orserdu |
| Pfizer INC. | $227.54 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $183.55 | 2019-2025 | |
| Amgen INC. | $156.19 | 2019-2021 | |
| Lilly USA, LLC | $143.56 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $127.50 | 2025 | Provenge |
| Gilead Sciences, INC. | $116.09 | 2021-2024 | |
| Genentech USA, INC. | $103.22 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $88.02 | 2024-2025 | |
| Geron Corporation | $86.09 | 2024-2025 | Rytelo |
| Seagen INC. | $79.92 | 2023 | Padcev |
| Beigene USA, INC. | $79.35 | 2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $77.54 | 2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $65.62 | 2019-2022 | |
| Astellas Pharma US INC | $64.99 | 2020 | |
| Mirati Therapeutics, INC. | $63.72 | 2024 | Krazati |
| Glaxosmithkline, LLC. | $58.05 | 2025 | Ojjaara |
| Sobi, INC | $57.94 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $52.02 | 2020-2024 | |
| Myriad Genetic Laboratories, INC. | $36.99 | 2024 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $34.99 | 2023 | Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $33.64 | 2024 | Libtayo |
| Blue Earth Diagnostics | $32.96 | 2025 | Posluma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.59 | 2025 | |
| Puma Biotechnology, INC. | $23.57 | 2019 | |
| Sirtex Medical INC | $20.16 | 2022 | |
| Array Biopharma INC | $19.75 | 2025 | Lorbrena, Braftovi |
| Agios Pharmaceuticals, INC. | $16.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kala Seetharman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.